Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

741 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
France's COVID-19 response: balancing conflicting public health traditions.
Atlani-Duault L, Chauvin F, Yazdanpanah Y, Lina B, Benamouzig D, Bouadma L, Druais PL, Hoang A, Grard MA, Malvy D, Delfraissy JF. Atlani-Duault L, et al. Among authors: yazdanpanah y. Lancet. 2020 Jul 25;396(10246):219-221. doi: 10.1016/S0140-6736(20)31599-3. Epub 2020 Jul 16. Lancet. 2020. PMID: 32682489 Free PMC article. No abstract available.
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. Yeni P, et al. HIV Med. 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x. HIV Med. 2009. PMID: 19200175 Free article. Clinical Trial.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
Treatment of Ebola virus disease.
Yazdanpanah Y, Arribas JR, Malvy D. Yazdanpanah Y, et al. Intensive Care Med. 2015 Jan;41(1):115-7. doi: 10.1007/s00134-014-3529-8. Epub 2014 Nov 11. Intensive Care Med. 2015. PMID: 25385474 No abstract available.
Drug assessment in the Ebola virus disease epidemic in west Africa.
Yazdanpanah Y, Horby P, van Griensven J, Mentre F, Nguyen VK, Malvy JM, Dunning J, Sissoko D, Delfraissy JF, Levy Y. Yazdanpanah Y, et al. Lancet Infect Dis. 2015 Nov;15(11):1258. doi: 10.1016/S1473-3099(15)00344-8. Lancet Infect Dis. 2015. PMID: 26531030 Free PMC article. No abstract available.
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. Molina JM, et al. N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1. N Engl J Med. 2015. PMID: 26624850 Free article. Clinical Trial.
REACTing: the French response to infectious disease crises.
Delfraissy JF, Yazdanpanah Y, Levy Y. Delfraissy JF, et al. Among authors: yazdanpanah y. Lancet. 2016 May 28;387(10034):2183-5. doi: 10.1016/S0140-6736(16)30059-9. Epub 2016 May 1. Lancet. 2016. PMID: 27145708 Free PMC article. No abstract available.
741 results